Leniolisib treatment for people with activated PI3K delta syndrome (APDS): a plain language summary of the phase 3 study

This is a plain language summary of an article originally published in Blood. Leniolisib is a drug developed to treat activated PI3K delta syndrome (APDS). APDS is a rare disease in which the immune system does not work correctly. People with APDS have a wide range of symptoms including infections, certain organs associated with the immune system becoming larger, and worse quality of life. This summary reports the results from a clinical study that aimed to understand if leniolisib is effective at treating people with APDS. The study showed that leniolisib improved the amounts of immune cells and antibodies (proteins that help the immune system to function). Leniolisib also reduced the size of participants' enlarged organs, and lowered the activity of the protein that causes APDS. There were no major safety concerns for participants who took leniolisib. These results indicate that leniolisib helps the immune system to work in a way that is closer to those without APDS. By helping the immune system, leniolisib may be able to improve the lives of people with APDS by making them feel better. Leniolisib may also prevent difficulties in completing activities in the daily lives of people with APDS. <b>Clinical Trial Registration:</b>NCT02435173 (ClinicalTrials.gov)

本内容为发表于《血液》（Blood）期刊的一篇学术文章的通俗概要。莱诺利布（leniolisib）是一款专为治疗活化PI3Kδ综合征（activated PI3K delta syndrome, APDS）研发的药物。APDS是一类罕见的免疫系统功能异常疾病，患者症状表现多样，涵盖感染、免疫相关器官肿大以及生活质量下降等。本概要报告了一项旨在评估莱诺利布治疗APDS患者有效性的临床研究结果。该研究显示，莱诺利布可提升免疫细胞与抗体（辅助免疫系统发挥功能的蛋白质）的水平；同时可缩小受试者的肿大器官体积，并降低引发APDS的致病蛋白活性。服用莱诺利布的受试者未出现重大安全相关不良事件。上述结果表明，莱诺利布可使患者的免疫系统功能趋近于健康人群。通过调节免疫系统功能，莱诺利布可通过改善患者身体状态提升其生活质量，此外还可帮助APDS患者克服日常活动障碍。<b>临床试验注册编号：</b>NCT02435173（ClinicalTrials.gov）